Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s PN-235?

PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).

CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board – Biotech Investments

Issuer: CureVac / Key word(s): Personnel 20.06.2023 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Appoints International Financial

June 21, 2023

Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer

Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option.

January 27, 2024

Balancing User Experience and Technical Complexity in Surgical Software Design

Neeraj Mainkar, VP of Software Engineering & Advanced Technology at Proprio In healthcare, the impact of well-designed medical devices reaches far beyond their physical form.

September 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.